Navigation Links
Peramivir Phase 2 Data for the Treatment of Outpatient Influenza to be Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:10/20/2008

rious or potentially life threatening influenza. BioCryst's partner, Shionogi & Co., Ltd., is preparing for a pivotal Phase 3 program with peramivir in subjects with influenza.

About BioCryst

BioCryst is an integrated biopharmaceutical company utilizing crystallography and structure-based drug design to develop a deep pipeline of novel therapeutics targeting major illnesses. BioCryst is currently advancing investigational new drugs discovered in-house in late-stage clinical trials for influenza and lymphoma. In addition, the Company has a pre-clinical portfolio of novel compounds, directed against infectious, cardiovascular, and autoimmune disease targets, to create long-term sustainable value. The Company's strategic alliances with the U.S. Department of Health and Human Services, Shionogi & Co., Ltd., Green Cross Corporation and Mundipharma International Holdings Ltd. validate its scientific foundation and the utility of its product candidates. For more information, please visit the Company's Web site at http://www.biocryst.com.

About Shionogi & Co., Ltd.

Shionogi & Co., Ltd., one of Japan's largest research-based pharmaceutical companies, develops, manufactures, distributes, imports and exports pharmaceuticals and diagnostics. Shionogi aims to provide innovative medicines which make a positive contribution to world-wide health. For additional company information, please visit Shionogi on the World Wide Web at http://www.shionogi.co.jp.

Forward-looking statements

This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements exp
'/>"/>

SOURCE BioCryst Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
2. Isolagen to Host Investor Conference Call to Present an Analysis of the Data from Phase III Wrinkle Studies
3. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
4. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
5. New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
6. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
7. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
8. BioXcel Forms a Corporate Advisory Board for Its Next Phase of Growth
9. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
10. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
11. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014  Discovery Laboratories, ... has been awarded a Phase II Small Business ... $3.0 million from the National Institute of Allergy ... of Health (NIH) to support the development of ... a medical countermeasure to mitigate acute and chronic/late-phase ...
(Date:10/1/2014)... Switzerland (PRWEB) October 01, 2014 ... the quality of the final product. However, while ... regulated, regulatory frameworks such as Good Manufacturing Practices ... the responsibility of the manufacturer to interpret these ... consistent weighing performance quality. METTLER TOLEDO experts have ...
(Date:10/1/2014)... Pfanstiehl has announced the launch of ... the USA under ICH ... for playing a key role in protein glycosylation.  ... that media supplementation with mannose can improve overall ... to Dr. Christopher Wilcox , VP, Business ...
(Date:10/1/2014)... (PRWEB) September 30, 2014 The participants ... designs, but to spending their own time adjusting, tweaking ... their complex designs were ready for judging. , “I ... design firm thought leader. “The entries showed a ... the physical characteristics of the print medium and the ...
Breaking Biology Technology:Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Comply with Weighing-Related Regulations in Pharma Manufacturing 2Pfanstiehl Launches cGMP-produced Mannose for Cell Culture Media Optimization & Glycoprotein Biosynthesis 2Array Architects Challenges Staff to Create with 3D Printer 2
... Much of Thursday's Digital Healthcare Conference ... facing plenty of them. , ,In today's issue, the ... from the Digital Healthcare Conference, you'll read about the ... are approaching those choices. Next issue, look for coverage ...
... to the north. The country brings to mind Mounties and ... Vancouver, British Columbia supports a thriving technology development environment, and ... a week there recently, meeting with some very savvy developers. ... some of the companies I met there. , , Imagis ...
... Brookfield-based Fiserv, Inc. , has ... management and billing software for large and mid-sized ... ,Interactive Technologies, headquartered in Summit, New Jersy, develops ... management companies, depositories, exchanges and other high-end providers ...
Cached Biology Technology:The tough choices facing health care 2The tough choices facing health care 3Imagis emerges from bumpy road 2Imagis emerges from bumpy road 3
(Date:9/30/2014)... Mediterranean each year, but its deep-blue waters host ... 1,000 alien species, including fish, crustaceans, and algae ... activities. In the open-access journal Frontiers in ... analyzed data from a new information system developed ... introduction of alien species has changed the native ...
(Date:9/30/2014)... Engineers at the University of California, San Diego, have ... tissue using a method that uses the pixels in ... method known as mesh-free simulation. , The researchers, led ... engineering at the Jacobs School of Engineering at UC ... this method at the CompIMAGE,14 conference in Pittsburgh this ...
(Date:9/30/2014)... assessment conducted by the Ocean Health Index rates ... in overall health. In addition, for the first ... 15 ocean regions beyond national jurisdiction (high-seas areas) ... climate, safeguarding biodiversity and providing sustainable food sources. ... index, a partnership led by scientists from UC ...
Breaking Biology News(10 mins):Biodiversity in the Mediterranean is threatened by alien species 2First comprehensive meshfree numerical simulation of skeletal muscle tissue achieved 2Rating the planet's oceans 2Rating the planet's oceans 3
... painful relationship with Campylobacter jejuni, we are just starting ... the leading cause of bacterial food-borne illness in the ... of diarrhea worldwide. The Centers for Disease Control estimate ... , While most sufferers recover after a few unpleasant ...
... University in Ithaca and Weill Cornell Medical College in ... protein biomarkers in cerebrospinal fluid that acts as a ... patients living with Alzheimer's disease. , The research will ... Annals of Neurology. , Right now, physicians ...
... 2006 -- A new study in Journal of the World ... smaller shrimp of the same gender when competing for food, ... adult males of the species are typically much smaller than ... and gender are important factors in acquiring food," says study ...
Cached Biology News:The biggest bug in gut discomfort 2Protein 'fingerprint' in spinal fluid could spot Alzheimer's disease 2Protein 'fingerprint' in spinal fluid could spot Alzheimer's disease 3
... Mini-Sub cell GT cell and PowerPac basic power ... of nucleic acids in agarose gels. The Mini-Sub ... with cables and electrodes, a 7 x 7 ... casting gates, and two 1.5 mm fixed-height combs ...
... 96 and PowerPac basic power supply are used ... in agarose gels. This Model 96 cell includes ... UV-transparent gel tray with fluorescent ruler, and a ... and 220-240 V, provides output of 10-300 V, ...
... basic power supply are used for submerged horizontal ... This Model 192 cell includes a buffer tank, ... with fluorescent ruler, and a gel caster. The ... provides output of 10-300 V, 4-400 mA, and ...
... The Sequi-Gen GT and PowerPac 3000 system, ... using a 38 x 30 cm vertical slab ... GT electrophoresis cell, which is capable of separating ... an integral plate chamber (IPC) assembly (IPC and ...
Biology Products: